Immunogenicity of biologics used in the treatment of moderate to severe psoriasis

The number of biologic drugs available for the treatment psoriasis continue to expand. However, being biological proteins and thus potentially immunogenic, there is evidence that anti-drug-antibodies develop against various therapeutic currently utilised. Although chimeric antibodies contain elements parental monoclonal are anti-drug occur even if a fully human protein these can impact on clinical efficacy safety. wide variation in reported level same different treatments highlighting issues with assays used antibody detection. Here we review data occurrence people treated agents.